A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers.

[1]  A. Schally,et al.  Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. , 2000, International journal of oncology.

[2]  A. Schally,et al.  Peptide analogs in the therapy of prostate cancer , 2000, The Prostate.

[3]  A. Schally,et al.  Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. , 2000, Cancer research.

[4]  Xiaopeng Wang,et al.  A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Schally,et al.  Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. , 1999, European journal of endocrinology.

[6]  E. Jenison,et al.  Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. , 1998, International journal of oncology.

[7]  A. Schally,et al.  Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. , 1997, Journal of the National Cancer Institute.

[8]  A. Schally,et al.  Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. , 1997, International journal of oncology.

[9]  M Kovacs,et al.  Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Schally,et al.  The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. , 1994, Human reproduction.

[11]  I. Magrath.  Targeted approaches to cancer therapy: Meeting held at stone house, NIH, bethesda, md, January 11–12, 1993 , 1994 .

[12]  A. Schally,et al.  High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. , 1993, The Journal of clinical endocrinology and metabolism.

[13]  J. Grandis,et al.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.

[14]  J. Field.  Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. , 1992, European journal of cancer. Part B, Oral oncology.

[15]  H. Friess,et al.  LH-RH receptors in the human pancreas. Basis for antihormonal treatment in ductal carcinoma of the pancreas. , 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.

[16]  N. Hayward,et al.  Analysis of gene amplification in head‐and‐neck squamous‐cell carcinomas , 1991, International journal of cancer.

[17]  A. Schally,et al.  Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Schally,et al.  Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  David J. Williams,et al.  New Sulfonyl‐Containing Materials for Nonlinear Optics: Semiempirical Calculations, Synthesis, and Properties. , 1991 .

[20]  David J. Williams,et al.  New sulfonyl-containing materials for nonlinear optics: semiempirical calculations, synthesis, and properties , 1990 .

[21]  K. Sikora,et al.  The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. , 1990, British Journal of Cancer.

[22]  K. Asano,et al.  Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. , 1989, British Journal of Cancer.

[23]  G. Fink,et al.  Solubilization of a large molecular weight form of the rat LHRH receptor. , 1987, The Journal of endocrinology.

[24]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[25]  I. Pastan,et al.  Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line. , 1985, The Journal of clinical investigation.

[26]  A. Schally,et al.  Hypothalamic and Other Peptide Hormones , 2003 .

[27]  M. Takagi,et al.  Evaluation of epidermal growth factor receptor in squamous cell carcinoma of the oral cavity. , 1992, Oral surgery, oral medicine, and oral pathology.

[28]  A. Kamer,et al.  Receptor phosphatases and cancer: Models for the therapeutic. Efficacy of somatostatin and LHRH analogues , 1992 .

[29]  D. Saranath,et al.  Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer. , 1992, European journal of cancer. Part B, Oral oncology.

[30]  M. Erdmann.  What is This? Downloaded from , 1991 .

[31]  C. Liebow.  Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous receptorstimulated tyrosine phosphorylation , 1991 .